The information within this section of the website is intended for patients prescribed Prostap DCS. Members of the public, and UK Healthcare Professionals should follow the relevant links.

Indications

Prostap DCS is indicated for the following:2,3

Prostate cancer

  • Metastatic prostate cancer
  • Locally advanced prostate cancer, as an alternative to surgical castration
  • As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer
  • As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression

Endometriosis

  • Management of endometriosis, including pain relief and reduction of endometriotic lesions
  • Endometrial preparation prior to intrauterine surgical procedures
  • Preoperative management of uterine fibroids to reduce their size and associated bleeding

Central precocious puberty

  • Central precocious puberty in girls under 9 years of age and boys under 10 years of age

Administration

Intramuscular (IM) or subcutaneous (SC) administration is available, depending on indication and dose.2,3

indications-figure1

Dual Chamber Syringe

Leuprorelin is delivered in a Dual Chamber Syringe (DCS) system which allows administration in under a minute.

abriefproductoverview-figure1

Needle size

Fine gauge needle

abriefproductoverview-figure14

indications-figure3

Contact

If you are a healthcare professional and have a clinical query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. IMS MIDAS standard unit sales (1,000) MAT/JAN/2014.
  2. Prostap SR DCS, Summary of Product Characteristics.
    Available at www.medicines.org.uk. Last accessed June 2017
  3. Prostap 3 DCS, Summary of Product Characteristics.
    Available at www.medicines.org.uk. Last accessed June 2017
  4. Takeda UK Ltd. Data on file, DF120604(2).
  5. NHS Electronic Drug Tariff. Label L. http://www.drugtariff.
    nhsbsa.nhs.uk/#/00280039-DC/DC00279755/Part VIIIA
    products
    Last accessed June 2017.
  6. IMS Health. Xponent BPI and HPA, MAT. March 2014

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers.

If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a
Practice Manager

Yes

I am a
Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.